ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "AMAG Pharmaceuticals, Inc." (AMAG) Report Updated: Jun 21, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"AMAG Pharmaceuticals, Inc." (AMAG)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: FPRX,AVXL,EXEL,ATHX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up upgrade
service keys

"AMAG Pharmaceuticals, Inc."© quotemedia

Company Profile

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company markets Feraheme in the United States and Canada; and as Rienso in the European Union. It sells Feraheme to authorized wholesalers and specialty distributors. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.